A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314)

Published:2018-05-02 Issue:8 Volume:65 Page:e27066
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Schafer Eric S.¹^ORCID,Rau Rachel E.¹,Berg Stacey¹,Liu Xiaowei²,Minard Charles G.¹,D'Adamo David³,Scott Rachael⁴,Reyderman Larisa³,Martinez Gresel³,Devarajan Sandhya⁵,Reid Joel M.⁵,Fox Elizabeth⁶,Weigel Brenda J.⁷,Blaney Susan M.¹

Affiliation:

1. Department of Pediatrics/Oncology, Dan L Duncan Comprehensive Cancer Center; Baylor College of Medicine; Houston Texas

2. Children's Oncology Group; Monrovia California

3. Eisai, Inc.; Woodcliff Lake New Jersey

4. Eisai, Ltd.; Hatfield United Kingdom

5. Mayo Clinic; Rochester Minnesota

6. Division of Oncology; Children's Hospital of Philadelphia; Philadelphia Pennsylvania

7. Department of Pediatrics; University of Minnesota; Minneapolis Minnesota

Funder

NCI (NIH)

Mayo Clinic Cancer Center

Eisai, Inc.

Cookies for Kids’ Cancer Foundation

Children's Oncology Group Foundation

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology, and Child Health

Reference38 articles.

1. Antimitotic inhibitors;Campos;Hematol Oncol Clin North Am,2012

2. Structural basis for the interaction of tubulin with proteins and drugs that affect microtubule dynamics;Downing;Annu Rev Cell Dev Biol,2000

3. Microtubule inhibitors: differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance;Perez;Mol Cancer Ther,2009

4. Identification of a distinct class of vinblastine binding sites on microtubules;Jordan;J Mol Biol,1986

5. Regulatory approvals of pediatric oncology drugs: previous experience and new initiatives;Hirschfeld;J Clin Oncol,2003

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current Status of Pharmacokinetic Research in Children: A Systematic Review of Clinical Trial Records;Current Reviews in Clinical and Experimental Pharmacology;2022-12-23

2. Natural products in chemotherapy of cancers;New Strategies Targeting Cancer Metabolism;2022

3. Targeted therapy in metastatic, recurrent and refractory Ewing sarcoma and osteogenic sarcoma. Review of literature;Russian Journal of Pediatric Hematology and Oncology;2021-04-07

4. Prioritization of Novel Agents for Patients with Rhabdomyosarcoma: A Report from the Children’s Oncology Group (COG) New Agents for Rhabdomyosarcoma Task Force;Journal of Clinical Medicine;2021-04-01

5. Unmet needs for relapsed or refractory Wilms tumour: Mapping the molecular features, exploring organoids and designing early phase trials – A collaborative SIOP-RTSG, COG and ITCC session at the first SIOPE meeting;European Journal of Cancer;2021-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3